Chiome Bioscience Inc. (TYO:4583)
Japan · Delayed Price · Currency is JPY 69.00
-1.00 (-1.43%)
Aug 6, 2026, 12:39 PM JST
Chiome Bioscience Financials Overview
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 601.75 | 593.29 | 780.81 | 682.46 | 630.82 | 712.93 |
Revenue Growth | -23.82% | -24.02% | 14.41% | 8.19% | -11.52% | 48.26% |
Gross Profit Gross Profit Growth | 355.46 | 355.58 | 432.85 | 398.6 | 348.86 | 422.46 |
Operating Income Operating Income Growth | -947.56 | -979.77 | -1,031 | -1,205 | -1,259 | -1,334 |
Net Income Net Income Growth | -949.86 | -982.78 | -1,021 | -1,220 | -1,243 | -1,480 |
Earnings Per Share EPS Growth | -13.85 | -14.47 | -17.54 | -24.62 | -28.26 | -36.74 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Drug Discovery Support Business Drug Discovery Support Business Growth | 601.75 | 593.29 | 577.86 | 682.46 | 630.82 | 609.92 |
Drug Discovery and Development Business Drug Discovery and Development Business Growth | - | - | 202.95 | - | - | 103.01 |
Total Total Growth | 601.75 | 593.29 | 780.81 | 682.46 | 630.82 | 712.93 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,142 | 1,205 | 2,063 | 1,326 | 1,727 | 1,791 |
Total Debt Total Debt Growth | 86.7 | 86.7 | 281.5 | 291 | 184 | 183 |
Net Cash (Debt) Net Cash Growth | 1,055 | 1,118 | 1,782 | 1,035 | 1,543 | 1,608 |
Net Cash Growth | -31.38% | -37.23% | 72.23% | -32.96% | -4.03% | -35.84% |
Net Cash Per Share Net Cash Per Share Growth | 15.38 | 16.47 | 30.61 | 20.88 | 35.09 | 39.92 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | - | -935.99 | -1,001 | -1,069 | -1,191 | -1,131 |
Capital Expenditures CapEx Growth | - | -40.08 | - | - | - | - |
Free Cash Flow Free Cash Flow Growth | - | -976.07 | -1,001 | -1,069 | -1,191 | -1,131 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 59.07% | 59.93% | 55.44% | 58.40% | 55.30% | 59.26% |
Operating Margin | -157.47% | -165.14% | -132.03% | -176.59% | -199.53% | -187.16% |
Pretax Margin | -157.31% | -165.10% | -130.32% | -178.03% | -196.23% | -205.69% |
Profit Margin | -157.85% | -165.65% | -130.73% | -178.77% | -197.03% | -207.58% |
FCF Margin | - | -164.52% | -128.16% | -156.67% | -188.81% | -158.68% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 6, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 9.18 | 12.27 | 22.50 | 10.32 | 13.66 | 11.02 |